MX2018001636A - Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5,-trifluoro-3,4,5,6-tetrahidropiridinas. - Google Patents
Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5,-trifluoro-3,4,5,6-tetrahidropiridinas.Info
- Publication number
- MX2018001636A MX2018001636A MX2018001636A MX2018001636A MX2018001636A MX 2018001636 A MX2018001636 A MX 2018001636A MX 2018001636 A MX2018001636 A MX 2018001636A MX 2018001636 A MX2018001636 A MX 2018001636A MX 2018001636 A MX2018001636 A MX 2018001636A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydropyridines
- trifluoro
- administration
- amino
- combination treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se dirige al uso combinado de inhibidor de BACE1 de Fórmula I (ver Fórmula) y un compuesto útil en la inmunoterapia de Tau activa o pasiva, un compuesto útil en la inmunoterapia de péptido Aß activa o pasiva, un antagonista de receptor de NMDA, un inhibidor de acetilcolina esterasa, un antiepiléptico, un fármaco antiinflamatorio, un inhibidor de la agregación de Tau o un SSRI para el tratamiento de trastornos neurodegenerativos o cognitivos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201500456 | 2015-08-10 | ||
DKPA201500707 | 2015-11-10 | ||
PCT/EP2016/068947 WO2017025532A1 (en) | 2015-08-10 | 2016-08-09 | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001636A true MX2018001636A (es) | 2018-05-07 |
Family
ID=56799425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001636A MX2018001636A (es) | 2015-08-10 | 2016-08-09 | Tratamiento de combinacion que comprende la administracion de 2-amino-3,5,5,-trifluoro-3,4,5,6-tetrahidropiridinas. |
Country Status (26)
Country | Link |
---|---|
US (1) | US10004738B2 (es) |
EP (1) | EP3334461A1 (es) |
JP (1) | JP2018529647A (es) |
KR (1) | KR20180035843A (es) |
CN (1) | CN107921138A (es) |
AR (1) | AR105656A1 (es) |
AU (1) | AU2016305260A1 (es) |
BR (1) | BR112017007306A2 (es) |
CA (1) | CA2993623A1 (es) |
CL (1) | CL2018000339A1 (es) |
CO (1) | CO2018000711A2 (es) |
CR (1) | CR20180093A (es) |
DO (1) | DOP2018000039A (es) |
EA (1) | EA201890257A1 (es) |
EC (1) | ECSP18010534A (es) |
HK (1) | HK1254354A1 (es) |
IL (1) | IL257072A (es) |
MA (1) | MA42611A (es) |
MX (1) | MX2018001636A (es) |
PE (1) | PE20180696A1 (es) |
PH (1) | PH12018500300A1 (es) |
RU (1) | RU2018104867A (es) |
SV (1) | SV2018005628A (es) |
TN (1) | TN2018000041A1 (es) |
TW (1) | TW201717948A (es) |
WO (1) | WO2017025532A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
DK1474395T3 (da) | 2002-02-12 | 2008-02-11 | Smithkline Beecham Corp | Nicotinamidderivater, der er nyttige som p38-inhibitorer |
AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
CA2799640C (en) | 2010-06-09 | 2018-10-16 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
MX2013008111A (es) | 2011-01-12 | 2013-10-30 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. |
PT2663561E (pt) | 2011-01-13 | 2016-06-07 | Novartis Ag | Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos |
US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
US8987255B2 (en) | 2011-06-07 | 2015-03-24 | Hoffmann-La Roche Inc. | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
JP2015531401A (ja) * | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するpde9i |
US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
EP2961749B1 (en) | 2013-03-01 | 2019-10-09 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
TW201609700A (zh) | 2014-02-19 | 2016-03-16 | H 朗德貝克公司 | 2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶作爲bace1抑制劑用於治療阿茲海默症 |
TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有bace1抑制活性之二氫噻及二氫衍生物 |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
-
2016
- 2016-08-04 TW TW105124755A patent/TW201717948A/zh unknown
- 2016-08-08 US US15/231,182 patent/US10004738B2/en not_active Expired - Fee Related
- 2016-08-09 JP JP2018506913A patent/JP2018529647A/ja active Pending
- 2016-08-09 WO PCT/EP2016/068947 patent/WO2017025532A1/en active Application Filing
- 2016-08-09 MX MX2018001636A patent/MX2018001636A/es unknown
- 2016-08-09 BR BR112017007306A patent/BR112017007306A2/pt not_active Application Discontinuation
- 2016-08-09 PE PE2018000223A patent/PE20180696A1/es not_active Application Discontinuation
- 2016-08-09 AR ARP160102441A patent/AR105656A1/es unknown
- 2016-08-09 MA MA042611A patent/MA42611A/fr unknown
- 2016-08-09 CA CA2993623A patent/CA2993623A1/en not_active Abandoned
- 2016-08-09 KR KR1020187005381A patent/KR20180035843A/ko unknown
- 2016-08-09 RU RU2018104867A patent/RU2018104867A/ru not_active Application Discontinuation
- 2016-08-09 CN CN201680045247.2A patent/CN107921138A/zh active Pending
- 2016-08-09 TN TNP/2018/000041A patent/TN2018000041A1/en unknown
- 2016-08-09 CR CR20180093A patent/CR20180093A/es unknown
- 2016-08-09 AU AU2016305260A patent/AU2016305260A1/en not_active Abandoned
- 2016-08-09 EA EA201890257A patent/EA201890257A1/ru unknown
- 2016-08-09 EP EP16756631.4A patent/EP3334461A1/en not_active Withdrawn
-
2018
- 2018-01-22 IL IL257072A patent/IL257072A/en unknown
- 2018-01-25 CO CONC2018/0000711A patent/CO2018000711A2/es unknown
- 2018-02-06 CL CL2018000339A patent/CL2018000339A1/es unknown
- 2018-02-07 SV SV2018005628A patent/SV2018005628A/es unknown
- 2018-02-08 DO DO2018000039A patent/DOP2018000039A/es unknown
- 2018-02-09 PH PH12018500300A patent/PH12018500300A1/en unknown
- 2018-02-09 EC ECIEPI201810534A patent/ECSP18010534A/es unknown
- 2018-10-19 HK HK18113430.1A patent/HK1254354A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112017007306A2 (pt) | 2018-03-27 |
ECSP18010534A (es) | 2018-04-30 |
SV2018005628A (es) | 2018-04-19 |
AU2016305260A1 (en) | 2018-02-15 |
US20170042895A1 (en) | 2017-02-16 |
HK1254354A1 (zh) | 2019-07-19 |
WO2017025532A1 (en) | 2017-02-16 |
TW201717948A (zh) | 2017-06-01 |
CN107921138A (zh) | 2018-04-17 |
JP2018529647A (ja) | 2018-10-11 |
RU2018104867A (ru) | 2019-09-12 |
IL257072A (en) | 2018-03-29 |
CO2018000711A2 (es) | 2018-05-10 |
KR20180035843A (ko) | 2018-04-06 |
MA42611A (fr) | 2018-06-20 |
PE20180696A1 (es) | 2018-04-23 |
CR20180093A (es) | 2018-06-05 |
CL2018000339A1 (es) | 2018-07-06 |
DOP2018000039A (es) | 2018-04-30 |
US10004738B2 (en) | 2018-06-26 |
PH12018500300A1 (en) | 2018-08-29 |
AR105656A1 (es) | 2017-10-25 |
TN2018000041A1 (en) | 2019-07-08 |
EA201890257A1 (ru) | 2018-07-31 |
CA2993623A1 (en) | 2017-02-16 |
EP3334461A1 (en) | 2018-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501355A1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
SA516380290B1 (ar) | نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة | |
PH12018500300A1 (en) | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetradropyridines | |
MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
PH12015502365A1 (en) | Bace1 inhibitors | |
MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
GEP20207172B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
TN2016000489A1 (en) | Carboxamide derivatives. | |
MX2020006228A (es) | Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas. | |
EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
PH12017501668A1 (en) | Bace1 inhibitors | |
PH12017501334A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
WO2017140684A3 (en) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. |